10 withdrawn. 10 Phase 2, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Withdrawn 10 |
| Phase 1 | 4 | Withdrawn 4 |
Follow Disease Progression: new trials by email Literature Review of Disease Progression trials Research Report on Disease Progression
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Oral Azacitidine (CC-486) Epigenetic Priming and Maintenance for Adult Acute Myeloid Leukemia (AML) Patients oral azacitidine (CC-486) - Acute Myeloid Leukemia | Phase 2 | Withdrawn | Yale University | 2023-11-01 | 2023-12-26 | |
| Radiation Omission in Patients With HER2 Overexpressing Tumors With Pathologic Complete Response Omit breast radiation - Breast Cancer, HER2-positive Breast Cancer | Phase 2 | Withdrawn | Armando Giuliano | 2023-07-01 | 2023-09-22 | |
| CPI-613 and Hydroxychloroquine for Patients With High Risk Myelodysplastic Syndrome CPI-613, Hydroxychloroquine - Myelodysplastic Syndromes, Progressive Disease | Phase 1 / Phase 2 | Withdrawn | Wake Forest University Health Sciences | 2021-05-01 | 2021-04-14 | |
| Efficacy and Safety of Ixazomib and Dexamethasone Refractory Autoimmune Cytopenia Ninlaro - Immune Thrombocytopenia, Warm Autoimmune Hemolytic Anemia | Phase 2 | Withdrawn | Assistance Publique - Hôpitaux de Paris | 2019-09-01 | 2019-10-28 | |
| Famitinib Plus Camrelizumab & Famitinib Alone & Famitinib Plus Ifosfamide in Advanced Osteosarcoma Famitinib, Ifosfamide, Camrelizumab - Effect of Drugs, Progression | Phase 1 / Phase 2 | Withdrawn | Peking University People's Hospital | 2019-08-15 | 2020-05-19 | |
| Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma Autologous CD19/CD22 Chimeric Antigen Receptor T-cells, Cyclophosphamide, Fludarabine - CD19 Positive, CD22 Positive | Phase 1 / Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2019-05-15 | 2023-08-21 | |
| Phase II Trial of EP4 Receptor Antagonist, AAT-007 (RQ-07; CJ-023,423) in Advanced Solid Tumors RQ-00000007, Gemcitabine - Prostate Cancer, Non-Small Cell Lung Cancer | Phase 2 | Withdrawn | University of Maryland, Baltimore | 2017-06-01 | 2019-11-04 | |
| Sulindac for Patients With AML Cytarabine, Sulindac - Acute Myeloid Leukemia | Phase 2 | Withdrawn | Massachusetts General Hospital | 2014-01-01 | 2017-02-17 | |
| Open-Label Study of TPI 287 for Patients With Metastatic Melanoma TPI 287 - Metastatic Melanoma | Phase 1 / Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2013-09-01 | 2013-04-05 | |
| Chemoprevention Trial for Uremia-Associated Urothelial Carcinoma Lycopene - Carcinoma, Transitional Cell | Phase 2 | Withdrawn | National Taiwan University Hospital | 80 | 2006-01-01 | 2008-09-26 |
Pathologic Complete Response (4) · Breast Neoplasms (2) · Leukemia, Myeloid, Acute (2) · Burkitt Lymphoma (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Transitional Cell (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lymphoma, Non-Hodgkin (1) · Melanoma (1) · Myelodysplastic Syndromes (1) · Neoplasm, Residual (1) · Neoplasms (1) · Prostatic Neoplasms (1) · Purpura, Thrombocytopenic, Idiopathic (1)
Disease Attributes (10) · Pathologic Processes (10) · Pathological Conditions, Signs and Symptoms (10) · Neoplasms (7) · Hematologic Diseases (5) · Hemic and Lymphatic Diseases (5) · Neoplasms by Histologic Type (5) · Leukemia (3) · Neoplasms by Site (3) · Skin Diseases (3) · Skin and Connective Tissue Diseases (3) · Breast Diseases (2) · Immune System Diseases (2) · Leukemia, Myeloid (2)
Azacitidine (1) · Cyclophosphamide (1) · Cytarabine (1) · Gemcitabine (1) · Hydroxychloroquine (1) · Ifosfamide (1) · Lycopene (1) · Sulindac (1) · TPI-287 (1) · camrelizumab (1) · cc-486 (1) · devimistat (1) · famitinib (1) · fludarabine (1) · grapiprant (1)
M.D. Anderson Cancer Center (2) · Armando Giuliano (1) · Assistance Publique - Hôpitaux de Paris (1) · Massachusetts General Hospital (1) · National Taiwan University Hospital (1) · Peking University People's Hospital (1) · University of Maryland, Baltimore (1) · Wake Forest University Health Sciences (1) · Yale University (1)
United States (6) · China (1) · France (1) · Taiwan (1)
Agop Y. Bedikian, MD, BS (1) · Amir Fathi, MD (1) · Armando Giuliano, MD, FACS, FRCSEd (1) · Bayard Powell, MD (1) · Jin S Im (1) · Lohith Gowda, MD (1) · Marcos de Lima, MD (1) · Martin Edelman, M.D., FACP (1) · Matthieu Mahevas (1) · Wei Guo, Ph.D. and M.D. (1) · Yeong-Shiau Pu, MD, PhD (1)
2018 (1), P30CA012197 (1), P30CA016672 (1), T32CA233414 (1)